Alkermes (ALKS) Retained Earnings (2011 - 2026)
Alkermes (ALKS) posted quarterly Retained Earnings of -$800.8 million for Q2 2026, up 7.63% year-over-year from -$744.0 million in Q2 2025, and little changed quarter-over-quarter from -$801.3 million in Q1 2026.
Alkermes (ALKS) Retained Earnings (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Retained Earnings for 16 consecutive years, with -$800.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings rose 7.63% year-over-year to -$800.8 million; the TTM figure through Jun 2026 stood at -$800.8 million (up 7.63% YoY), while the FY2025 annual figure was -$734.8 million, up 24.75% from the prior year.
- Retained Earnings steadied at -$800.8 million in Q2 2026 per ALKS's latest filing, from -$801.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$734.8 million in Q4 2025 and bottomed at -$1.7 billion in Q1 2023.
- Historically, Retained Earnings has averaged -$1.2 billion across 5 years, with a median of -$1.3 billion in 2024.
- Annual changes were most pronounced in 2023 — Retained Earnings fell 10.41% — and 2025, when it soared 30.17%.
- Alkermes' Retained Earnings stood at -$1.7 billion in 2022, then increased by 20.94% to -$1.3 billion in 2023, then rose by 27.32% to -$976.5 million in 2024, then rose by 24.75% to -$734.8 million in 2025, then decreased by 8.98% to -$800.8 million in 2026.
- Business Quant data shows ALKS's Retained Earnings at -$800.8 million in Q2 2026, -$801.3 million in Q1 2026, and -$734.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 3.75 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | -800.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -800.77 Mn |
| Mar 31, 2026 | -801.27 Mn |
| Dec 31, 2025 | -734.79 Mn |
| Sep 30, 2025 | -784.14 Mn |
| Jun 30, 2025 | -866.90 Mn |
| Mar 31, 2025 | -953.99 Mn |
| Dec 31, 2024 | -976.46 Mn |
| Sep 30, 2024 | -1.12 Bn |
| Jun 30, 2024 | -1.22 Bn |
| Mar 31, 2024 | -1.31 Bn |
| Dec 31, 2023 | -1.34 Bn |
| Sep 30, 2023 | -1.46 Bn |
| Jun 30, 2023 | -1.50 Bn |
| Mar 31, 2023 | -1.74 Bn |
| Dec 31, 2022 | -1.70 Bn |
| Sep 30, 2022 | -1.67 Bn |
| Jun 30, 2022 | -1.61 Bn |
| Mar 31, 2022 | -1.58 Bn |
| Dec 31, 2021 | -1.54 Bn |
| Sep 30, 2021 | -1.54 Bn |